

Research Activities Newsletter November/December 2022

In the News: Congratulations to the following awardees!!



Michael LaMonte, Research Professor, is PI on a continuation award from the Kent County Memorial Hospital/NIH, for the research project entitled, *Racial/Ethnic Disparities in Heart Failure: A Cross Cohort Collaboration*. The study is evaluating the magnitude and potential causes of racial/ethnic and sex disparities in incident heart failure and its subtypes and their prognosis in 130,000 men and women from 10 pooled cohorts.



Elizabeth Mietlicki-Baase, Assistant Professor of Exercise and Nutrition Sciences is PI on a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the research project entitled, *Effects of Mesolimbic Amylin Signaling on Macronutrient Intake*. The project is assessing mechanisms by which the hormone amylin suppresses food intake and body weight by influencing macronutrient intake, with particular focus on its actions in the ventral tegmental area (VTA), a key nucleus in the brain important for feeding and other motivated behaviors.



Jennifer Temple, Professor of Exercise and Nutrition Sciences and Community Health and Health Behavior, is PI on a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH the research project entitled, *The Role of Food Insecurity and Sensitization in Excess Weight Gain in Adolescents from Low to Moderate Income Households*. This study is examining a novel behavioral phenotype, sensitization to repeated intake of snack food, and its relationship with food insecurity, body weight and weight change over time in a cohort of adolescents from moderate to low-income families. **Gregory Wilding**, Professor and Chair of Biostatistics, is Co-Investigator.



Jean Wactawski-Wende, Dean of SPHP and SUNY Distinguished Professor of Epidemiology and Environmental Health, and **Jessica Kruger**, Clinical Assistant Professor of Community Health and Health Behavior, received a new award from the Mother Cabrini Health Foundation for the project entitled, *University at Buffalo and Mother Cabrini Health Foundation Mobile Health Clinic*. The funding will be utilized to purchase and build a mobile medical health unit, which will provide resources and services for high need communities across Buffalo and the greater WNY region. The mobility of the unit addresses the barriers of transportation for many, filling gaps with the existing healthcare infrastructure to address needs where community members reside. The overall goal is to reduce health inequities affecting their lives.



Dr. Wactawsk-Wende also received a continuation of the award from the National Heart, Lung and Blood Institute/ NIH for the project entitled *Women's Health Initiative (WHI) – Regional Center*. As the Northeast Regional Center for the WHI, the study will continue to collect health outcomes and new risk factor data in the postmenopausal women who have been participants since the study was launched in 1993. With 70,000 remaining active participants now aged between 78 and 103 years, the extension award will continue to focus on heart failure, atrial fibrillation, VTE, coronary heart disease, peripheral arterial disease (PAD), stroke and sleep disorders, as well as assess dementia, fracture, falls, physical function, and mortality. Co-Investigators from EEH are **Hailey Banack**, Research Assistant Professor, **Michael LaMonte**, Research Professor, **Amy Millen**, Associate Professor, and **Heather Ochs-Balcom**, Associate Professor.



Gregory Wilding, Professor and Chair of Biostatistics, is a Co-Investigator on a continuation award from National Institute of Dental & Craniofacial Research/NIH, (PI: Jason Kay, Oral Biology), for the research project entitled, *A Role for Immune Cell Plasticity in Commensal Survival and Escalation of Inflammation*. The project continues to study the conditions and molecular mechanisms by which commensals can act as pathobionts, which is the first step in developing new targets and strategies for the prevention and treatment of oral bacterial-associated inflammatory diseases.

In This Issue

In the News: Congratulations to the Following Awardees 1
Grant Clinic..... 2
NIH Funding Opportunities
 Request for Applications (RFA) 4
 Program Announcements Reviews in an Institute (PAR) 9
Individual Actions for Sustainability 11

Grant Clinic

GENERAL NOTICE

Free Crash Course in NIH Funding: 2023 NIH Grants Conference on Feb. 1-2, 2023

On February 1-2, 2023, the NIH will be hosting a conference for researchers to brush up on the latest policies and information. This conference is for researchers who are new to NIH grants as well as experienced researchers who are looking to better understand the processes and policies behind NIH funding. The [2023 NIH Grants Conference](#) is a free and virtual event. During this 2-day live event, NIH and HHS experts will share policies, resources, guidance, and case studies in informative and engaging sessions. Save the dates and add the [February 1](#) and [February 2](#) events to your calendar for easy access.

Here are some highlights of what you can expect from the conference:

- **Learn** about NIH grants policies! The jam-packed [agenda](#) offers 2 days of sessions designed to clarify the NIH grants process and policies, and opportunities to engage with presenters through Q&A and chat features.
- **Interact** with NIH experts! the 1:1 Meet the Experts which are 20-minute chats between attendees and NIH staff, designed for more specific research and administrative questions.
- **Engage** and network with your peers! The attendee search feature allows you to filter through over 13,000 attendees to network and connect with colleagues. Networking Lounges are also available for attendees to share tips and attend special events.
- **Gather** resources to use and share with colleagues! Explore the Exhibit Hall, where you’ll encounter NIH staff and an abundance of resources located at over 45 NIH Institute, Center, and Special Program booths.

Registration is free and includes your personal “All Access Pass” to the virtual [NIH Grants Conference 2022-2023 season](#). Once registered and logged into the conference site, you are free to explore the 2-day agenda, on-demand library of related resources, and create your personal schedule.

In the meantime, explore the [PreCon event](#) recordings and materials for deep dives into select NIH grant topics. We hope to see you soon at [#NIHGrantsConf!](#)

NOTICE OF INTENT TO PUBLISH

[NOT-ES-23-003](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Reporting Back Environmental Health and Non-genomic Research Results

The National Institute of Environmental Health Sciences (NIEHS), in partnership with the NIH Office of Science Policy (OSP) and the [All of Us Research Program](#), intends to publish an FOA for applications that identify, develop, and test strategies for reporting back environmental health and non-genomic research results to study participants and/or key partners. Applications will be sought that advance the field of RBRR for environmental health and non-genomic research results to help establish best practices/guidelines through research and evaluation; improve understanding of perceived risks and benefits, challenges, and obstacles to inform the practice of RBRR; and better understand how RBRR can help improve health equity and reduce health disparities.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-DA-24-002](#) – **Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment**

This notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM; e.g., lesbian, gay, bisexual). This notice applies to due dates on or after **January 5, 2023**, and subsequent receipt dates through **January 8, 2026**.

[NOT-AI-22-072](#) – **Opportunities for HIV Cure Interventions at the Time of ART Initiation**

This NOSI serves to identify new opportunities for cure strategies during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART, with the ultimate goal of achieving a sustained ART-free HIV remission. Clinical trials are not allowed, but the use of samples from clinical trials supported by other funding mechanisms is encouraged. For funding consideration, applicants must include “**NOT-AI-22-072**” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. This Notice applies to due dates on or after **January 7, 2023** and subsequent receipt dates through **September 7, 2025**.

[NOT-DA-24-003](#) – **Administrative Supplement for Rapid Translation of Substance Use and Addiction Epidemiology and Prevention Intervention Research**

This NOSI invites requests for administrative supplements to existing NIH grants and cooperative agreements that will translate findings between epidemiology and prevention intervention research related to substance use and addiction. This NOSI is to incentivize cross-disciplinary collaboration by inviting administrative supplement requests that will either a) extend an epidemiological project into prevention intervention or b) extend a prevention intervention project into epidemiological research. The proposed supplemental activities must be within the scope of the parent award. This Notice applies to due dates on or after **January 15, 2023**, and subsequent receipt dates through **January 7, 2026**.

[NOT-OD-23-031](#) – **Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars**

This is the reissuance of NOSI ([NOT-OD-20-054](#)). The goal of this program is to enhance the retention of investigators facing critical life events who are transitioning from mentored career development awards to research independence and to minimize departures from biomedical research workforce. This supplement program is intended to ensure continuity of research among recipients of mentored career development awards

by providing supplemental research support to help sustain the investigator's research during a period in which the PD/PI experiences critical life events which have the potential to impact research progress or potential productivity. This Notice applies to due dates on or after **January 16, 2023** through **September 30, 2025**.

[NOT-OD-23-032](#) – Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH research Project Grant Awards

This is the reissuance of NOSI ([NOT-OD-20-055](#)). The goal of this program is to enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their first independent research project grant award or to a second new NIH research project grant award. This program supports “at-risk” investigators as identified in the NIH Next Generation Researchers Initiative (see <https://grants.nih.gov/ngri.htm>). This Notice applies to due dates on or after **January 16, 2023** through **September 30, 2025**.

[NOT-DA-24-004](#) – Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders

The goal of this announcement is to encourage basic preclinical research aimed at identifying and targeting specific enzymes and pathways that play a key role in epigenetic changes induced by addictive drugs with the goal of developing pharmacological tools, methods, and therapeutic interventions for the treatment of substance use disorders and addiction. This applies to due dates on or after **February 5, 2023** through **January 8, 2026**.

[NOT-DA-23-013](#) – Research to Address ‘Ending the HIV Epidemic’ Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV

The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the ‘Ending the HIV Epidemic in the U.S. (EHE)’ initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **January 8, 2027**.

[NOT-AR-23-004](#) – Promoting Research Opportunities on HIV/AIDS in NIAMS

The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission. Applications should meet the NIH HIV/AIDS Research Priorities and Guidelines: <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html>. This Notice applies to due dates on or after **February 5, 2023**, and subsequent receipt dates through **January 8, 2028**.

[NOT-DA-23-012](#) – Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders

The purpose of this Notice is to inform potential applications to the [NIDA](#) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. This Notice applies to due dates on or after **February 5, 2023** through **February 8, 2026**.

[NOT-HD-22-043](#) – Implementation Science to Advance Maternal Health and Maternal Health Equity for the IMPROVE initiative

The purpose of this NOSI is to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality (MMM). This NOSI will support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve preconception, pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity. This Notice applies to due dates on or after **February 6, 2023** through **May 7, 2025**.

[NOT-OD-23-029](#) – Research on Gender Measurement (Admin Supp Clinical Trial Optional)

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research testing gender terminology (e.g., woman, man, nonbinary) for measuring current gender identity as part of the two-step method of data collection (sex assigned at birth and current gender identity). Individual(s) must hold an active grant or cooperative agreement from NIH. This NOSI will support supplements for all activity codes. **Application Due Date:** February 13, 2023

[NOT-AG-22-030](#) – **Small Research Grants for Innovations in Health Longevity Research**

This NOSI invites applications for small research grants that align with the goals of the National Academy of Medicine's [Healthy Longevity Grand Challenge](#), as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This Notice applies to due dates on or after **February 16, 2023**, and subsequent receipt dates through **May 7, 2023**.

[NOT-OD-23-002](#) – **Administrative Supplements to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentorship**

Participating Institutes and Centers (ICs) are inviting applications to support administrative supplements to existing NIH awards to support scientists who have demonstrated compelling commitments and contributions to mentorship and enhancing diversity, equity, inclusion, and accessibility (DEIA) in the biomedical sciences. The intent of this NOSI is to reach those individuals with limited NIH support. This is a reissue of NOSI [NOT-OD-22-057](#), with modified eligibility requirements, including mechanisms and citizenship status. **Application Due Date:** February 17, 2023.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

FEBRUARY 2023 DUE DATES

[RFA-DA-23-036](#) – (R01 – Clinical Trial Not Available)

Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity

This FOA will support projects that investigate the effects of addictive substances on developmental trajectories of molecularly-defined central nervous system (CNS) cells and circuits. Emphasis is on carrying out systematic and highly granular quantitative characterizations of the impact of *in utero* and/or postnatal substance exposures on the numbers, spatial distribution, connectivity and states of molecularly-defined cells and cell classes, across whole brains or large spatially-defined structures and distributed circuits of clinical relevance. **Application Due Date:** February 2, 2023

[RFA-DA-23-045](#) (UG1 – Clinical Trial Not Allowed)

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats

The goal of this FOA is to seek research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts. This FOA is part of the NIH's Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. More information about the HEAL Initiative is available at <https://heal.nih.gov/>. **Application Due Date:** February 3, 2023

[RFA-DA-23-046](#) (RM1 – Clinical Trial Optional)

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On

NIDA seeks applications for multi-project RM1 Opioid Use Disorder Quality Measurement and Management Research Centers (OUD-QM²RCs). OUD-QM²RCs will involve researchers and a partner with a deployed or in-development quality measurement strategy for opioid use disorder treatment that rigorous, scientific research could substantially advance. The ultimate goal is the creation of feasible, efficient quality measurement systems that provide meaningful information to help patients, families, and payors fairly compare and select providers and to help clinicians and providers improve patient outcomes. **Application Due Date:** February 3, 2023

[RFA-DA-23-051](#) (R01 – Clinical Trials Optional)

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants

Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. Research should be conducted within populations disproportionately affected by opioid use disorder, mental illness, or death by suicide. Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. **Application Due Date:** February 3, 2023

[RFA-DA-23-059](#) (R01 Clinical Trial Optional)

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program

The purpose of this FOA is a) to uncover novel mechanisms underlying the bidirectional relationship between sleep/circadian rhythm and Opioid Use Disorder (OUD), and b) to reveal new insights into sleep and/or circadian-based predictors of OUD medication treatment response and outcomes. Sleep and circadian dysfunctions are frequently co-morbid with OUD and may have clinical utility in identifying individuals at risk for poor treatment response and relapse. **Application Due Date:** February 10, 2023

[RFA-DA-23-060](#) (U01 Clinical Trial Optional)

HEAL Initiative – Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center

The purpose of this FOA is to invite institutions to participate as the Leadership and Data Coordinating Center (LDCC) for the Sleep Predictors of Opioid Use Disorder (OUD) Treatment and Outcomes Program. The overall goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to delineate sleep and/or circadian-based predictors of OUD treatment response and outcomes. **Application Due Date:** February 10, 2023

[RFA-CA-22-052](#) (U01 – Clinical Trial Not Allowed)

Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms

The National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA), and National Center for Complementary and Integrative Health (NCCIH) invite Cooperative Agreement (U01) applications that propose a prospective cohort study to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors, currently receiving treatment, comparing those using with those not using cannabis and cannabinoids. Applicants responding to this FOA should be aware of the companion FOA ([RFA-CA-22-053](#)) for the U24 coordination center. **Application Due Date:** February 18, 2023

[RFA-ES-22-008](#) (R01 Clinical Trial Not Allowed)

[RFA-ES-22-009](#) (R21 Clinical Trial Not Allowed)

Biological Basis for How Environmental Exposures Impact Risk for Psychiatric Disorders

The objective of this FOA is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. **Application Due Date:** February 22, 2023

[RFA-CA-23-020](#) (UG1 Clinical Trial Required)

NCI Cancer Screening Research Network: Accrual, Enrollment, and Screening Sites (ACCESS) Hub

[RFA-CA-23-021](#) (UG1 Clinical Trial Required)

NCI Cancer Screening Research Network: Statistics and Data Management Center

[RFA-CA-23-022](#) (UG1 Clinical Trial Required)

NCI Cancer Screening Research Network: Coordinating and Communication Center

These FOA's will support a comprehensive effort by the National Cancer Institute (NCI) to provide infrastructure to develop the Cancer Screening Research Network (CSRN). The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. Each key component of the CSRN program is described briefly below:

- **CSRN ACCESS Hubs** will establish multi-disciplinary teams to recruit participants to CSRN trials and studies, conduct the screening protocols, and participate in the scientific development and implementation of those trials and studies.
- **CSRN Statistics and Data Management Center (SDMC)** will provide statistical expertise and centralized data management, quality control, and reporting in support of CSRN clinical trials and other cancer screening studies.
- **CSRN Coordinating and Communication Center (CCC)** will provide cancer screening expertise and clinical trial leadership and is responsible for the coordination of all aspects of study operations, as well as the development and implementation of communication activities.

Application Due Date: February 28, 2023

[RFA-CA-22-035](#) (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-CA-22-036](#) (K99/R00 – Independent Clinical Trial Required)

[RFA-CA-22-037](#) (K99/R00 – Independent Basic Experimental Studies with Humans Required)

NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers

This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply. **Application Due Date:** February 28, 2023

MARCH 2023 DUE DATES

[RFA-DA-24-004](#) – (R21 Clinical Trial Not Allowed)

[RFA-DA-24-003](#) – (R01 Clinical Trial Not Allowed)

Targeting Inflammosomes in Substance Abuse and HIV

The goal of this FOA is to encourage research to explore mechanisms of inflammasome activation, humoral immune reaction and potential antibody-mediated enhancement, and their link to immune functions in people with HIV and substance use disorders (SUDs). **Application Due Date:** **R21** - March 15, 2023; **R01** - March 16, 2023

[RFA-DA-24-002](#) (R61/R33 – Clinical Trial Not Allowed)

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders

This FOA aims to promote research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs. **Application Due Date:** March 23, 2023

[RFA-HD-24-006](#) (R21 – Clinical Trial Not Allowed)

Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research

The purpose of this FOA is to utilize archived HIV/AIDS data and biospecimen collections to generate new research questions and findings related to epidemiology, pathogenesis, treatment, prevention, clinical manifestations, and HIV-associated co-infections in maternal, pediatric, and adolescent populations. **Application Due Date:** March 29, 2023

MULTIPLE DUE DATES

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Due Dates:** February 21, 2023, November 14, 2023, July 12, 2024, March 12, 2025

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. **Application Due Dates:** February 21, 2023, November 14, 2023, July 12, 2024, March 12, 2025

[RFA-OD-22-028](#) (R01 Clinical Trial Optional)

The Intersection of Sex and Gender Influences on Health and Disease

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in

understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#). **Application Due Dates:** November 22, 2023, November 22, 2024

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. **Applications Due:** March 20, 2023, November 15, 2023, March 20, 2024

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: February 14, 2023, October 13, 2023, February 13, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nhlbi.nih.gov.

Application Due Dates: June 20, 2023; October 19, 2023, June 20, 2024; and October 21, 2024.

[RFA-CA-22-050](#) (R01 Clinical Trial Optional)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP)

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. **Application Due Dates:** June 6, 2023, February 6, 2024

[RFA-DA-23-013](#) (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-061](#) (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-028](#) (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. **Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

NCI Outstanding Investigator Award

The Outstanding Investigator Award is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. **Application Due Dates:** Multiple Dates; **Expires:** Feb. 15, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-23-072](#) – (R13 Clinical Trial Not Allowed)

FDA Support for Conferences and Scientific Meetings

The purpose of the FDA Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. *A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.* **Application Due Dates:** Multiple Dates; **Expires:** Oct. 11, 2025

[PAR-23-051](#) – (U01 Clinical Trial Not Allowed)

[PAR-23-052](#) – (UH2 Clinical Trial Not Allowed)

Mechanistic links between diet, lipid metabolism, and tumor growth and progression

The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 24, 2025

[PAR-23-053](#) – (R61/R33 – Clinical Trial Optional)

Research Infrastructure Development for Interdisciplinary Aging Studies

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-058](#) – (R03 Clinical Trial Optional)

NCI Small Grants Program for cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus)

This funding opportunity supports small research projects on cancer that can be carried out in a short period of time with limited resources. This grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-034](#) – (R01 Clinical Trial Optional)

NLM Research Grants in Biomedical Informatics and Data Science

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of

complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. **Application Due Dates:** Multiple Dates. **Expiration:** January 8, 2026

[PAR-23-036](#) – (R21 Clinical Trial Not Allowed)

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders

This FOA encourages applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. **Application Due Dates:** Multiple Dates. **Expiration Date:** January 8, 2026

[PAR-23-057](#) – (R01 Clinical Trial Required)

NIA Multi-site Clinical Trial Implementation Grant

This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the [NIA website](#). **Application Due Dates:** Multiple Dates. **Expires:** January 8, 2026

[PAR-23-037](#) – (U01 Clinical Trial Optional)

Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities

The purpose of this FOA is to invite applications for multisite clinical trials and large-scale observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice [NOT-HD-19-034](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

Foundation Funding Opportunities

[Robert Wood Johnson Foundation](#)

Evidence for Action: Innovative Research to Advance Racial Equity

This funding is focused on studies about upstream causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals' options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem. Submissions from teams that include both U.S. and international members are eligible, but the lead applicant must be based in the United States. **Applications are accepted on a rolling basis.**

[Robert Wood Johnson Foundation](#)

Pioneering Ideas: Exploring the Future to Build a Culture of Health

These proposals are primed to influence health equity in the future. Ideas should address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, ideas are welcomed that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. **Applications are accepted on a rolling basis.**

Individual Actions for Sustainability

UB is home to a series of three solar arrays which comprise of more than 22,600 solar panels which produce renewable energy from ground-mounted solar arrays. Locations on the North Campus are near Bizer Creek, behind the Creekside Village student apartments, and near the Amherst bike path on the eastern edge of the campus.

Click on the link below to learn more about how UB is committed to sustainability and achieving climate neutrality by 2030. <https://www.buffalo.edu/ubnow/stories/2022/12/on-site-solar.html>

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras

